CA2568827A1 - Organic radiographic contrasting agents for medical devices - Google Patents
Organic radiographic contrasting agents for medical devices Download PDFInfo
- Publication number
- CA2568827A1 CA2568827A1 CA002568827A CA2568827A CA2568827A1 CA 2568827 A1 CA2568827 A1 CA 2568827A1 CA 002568827 A CA002568827 A CA 002568827A CA 2568827 A CA2568827 A CA 2568827A CA 2568827 A1 CA2568827 A1 CA 2568827A1
- Authority
- CA
- Canada
- Prior art keywords
- medical device
- halogen
- radio
- contrasting agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims abstract description 55
- 125000003118 aryl group Chemical group 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 39
- 125000002723 alicyclic group Chemical group 0.000 claims abstract description 28
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 28
- 125000005843 halogen group Chemical group 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 68
- 229920002988 biodegradable polymer Polymers 0.000 claims description 18
- 239000004621 biodegradable polymer Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003852 triazoles Chemical class 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- -1 poly(ester amide Chemical class 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 7
- 229920001610 polycaprolactone Polymers 0.000 claims description 7
- 239000004632 polycaprolactone Substances 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- 229920001710 Polyorthoester Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical class CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000012633 leachable Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical class C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- KSXFNGRHPAHIQJ-UHFFFAOYSA-N 1,2,4-triiodobenzene Chemical compound IC1=CC=C(I)C(I)=C1 KSXFNGRHPAHIQJ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000002837 carbocyclic group Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical class CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical class C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229920005787 opaque polymer Polymers 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical class 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical class COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000807 solvent casting Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008096 xylene Chemical class 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
Abstract
The present invention discloses an organic radiographic contrasting agent containing an aliphatic or alicyclic backbone and multiple halogen-substituted aromatic groups. Each of the halogen-substituted aromatic groups in the radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone. The present invention also discloses a radio-opaque polymeric material comprising the radiographic contrasting agent and at least one polymer. The radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.
Description
ORGANIC RADIOGRAPHIC CONTRASTING AGENTS FOR MEDICAL
DEVICES
Field of Invention The present invention relates to an organic contrasting agent that provides enhanced contrasting intensity in radiographic imaging of medical devices and a polymeric material containing the organic contrasting agent and at least one polymer.
Background of Invention It is important that medical devices are biocompatible since most medical devices interface with biological tissues during use. Therefore, medical devices are preferred to be prepared from biocompatible materials.
More specifically, the ideal materials for medical devices should satisfy at least the following requirements: (1) conformable, i.e., conform to the biological structure without inducing detrimental stress, (2) robust, i.e., withstand handling during fabrication and implantation, and (3) chemically inert to body tissue and body fluids. However, conventional materials used for the construction of medical devices, such as stainless steel and other alloys, not only are physically rigid, but also cause inflammatory reactions or other side effects when interfacing with biological tissues.
To overcome these problems, synthetic poiymeric materials, including both biodegradable and non-biodegradable polymers, have been widely used to fabricate medical devices. Common biodegradable polymers include polylactide (PLA) polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyphosphoesters (PPE), polyorthoesters, polyanhydrides, polyphosphazene, poly(esteramide) (PEA), and copolymers and mixtures thereof. Non-biodegradable polymers are also known as nonabsorbable polymers. Common nonabsorbable polymeric materials - 1 - , include, but are not limited to: silicone elastomers, polyutheranes, polymethyl methacrylate, Dacron , Teflon , and derivatives thereof. However, these polymeric materials are not radio-opaque. Consequently, medical devices made from these polymers cannot be visualized by means of radiographic imaging. The ability to see the radiographic image of a medical device being used in, or implanted within, the body is very important since radiographic imaging provides a physician the ability to monitor and adjust the medical device during operation. For some medical implant applications, X-ray visibility is mandatory.
To achieve desirable radio-opacity in the polymeric materials used for medical implants, one conventional method utilizes inorganic radiographic contrasting agents, such as barium sulfate, zirconium dioxide, or bismuth halides as additives or fillers in the polymeric material to form a radio-opaque polymeric matrix. However, these inorganic agents do not mix well with polymeric materials and may cause phase separation or even clumps in the radio-opaque polymeric matrix. The phase separation problem is further aggravated since high concentrations {around 10%, and often times 20-30%
by weight) of these inorganic radiographic contrasting agents -are routinely used to obtain the required radio-opacity. The incompatibility between the polymeric and inorganic phases compromises the physicomechanical properties (e.g., lubricity and robustness) of the polymer matrix. Another disadvantage of using inorganic radiographic contrasting agents is the leach-out of these inorganic agents from the radio-opaque polymeric matrix, which adversely compromises the mechanical strength of the polymeric material.
An alternative approach to introduce radio-opacity into polymeric materials is to synthesize polymers having covalently bound bromine or iodine atoms that may produce a radiographic contrasting effect (See U.S. Patent No. 6,426,145). One radio-opaque composition of the prior art comprises a polymer having a non-leachable radio-opaque moiety covalently attached to the polymer (See U.S. Patent No. 6,599,448), wherein the non-leachable radio-opaque moiety includes halogen substituted aromatic groups. The prior art has also disclosed a radio-opaque polymeric material comprising a diphenol-based monomer unit substituted with at least one bromine or iodine atom (See U.S. Patent No. 6,852,308). However, preparations of these prior art radio-opaque polymers require synthesis of radiographic contrasting monomer units, which may increase the technical complexity and production cost.
Thus, there remains a need for a radiographic contrasting agent that is compatible with polymeric materials and provides enhanced contrasting intensity as well.
Summary of the Invention Accordingly, the present invention provides a radiographic contrasting agent comprising an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)--, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -(SO)NH-, and triazole. Preferably, the inventive radiographic contrasting agent comprises at least three halogen-substituted aromatic groups.
The present invention also provides a radio-opaque polymeric material comprising an organic radiographic contrasting agent and at least one polymer, wherein the organic radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer, and the organic radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three = CA 02568827 2006-11-24 halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole. The at least one polymer may be at least one biodegradable polymer, at least one non-biodegradable polymer, or a mixture thereof.
In another aspect, the present invention provides a medical device, wherein at least one portion of the medical device is radio-opaque, the at least one radio-opaque portion of the medical device comprising a radio-opaque polymeric material, which comprises a radiographic contrasting agent and at least one polymer, wherein the radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -(SO)NH-, and triazole. Preferably, the medical device is an implantable medical device. More preferably, the medical device is a cardiovascular or peripheral drug eluting stent.
Detailed Description of the Invention The present invention provides a radiographic contrasting agent, comprising an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups. As used herein, "an aliphatic backbone" denotes an organic moiety consisting of carbon atoms linked in open chains, and "an alicyclic backbone" denotes an organic moiety consisting of carbon atoms forming one or more rings that are not aromatic.
Each of the at least two halogen-substituted aromatic groups in the inventive radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone through a linkage group. The linkage group is selected from oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -~SO)NH-, or triazole. As used herein, "(CO)" denotes a carbonyl moiety; "(SO)" denotes a sulfinyl moiety; and "(SO2)" denotes a sulfonyl moiety. The linkage group links the aliphatic or alicyclic backbone and the at least two halogen-substituted aromatic groups through covalent bonds. The linkage group expressed as "-linkage-" denotes a linkage in the manner as follows: (the aliphatic or alicyclic backbone)-linkage-(one of the at least two halogen-substituted aromatic groups). For example, -(CO)O-" denotes a linkage as follows: (the aliphatic or alicyclic backbone)-(CO)O-(one of the at least two halogen-substituted aromatic groups). Preferably, the linkage group of the present invention is -NH(CO)-, -O(CO)-, or triazole. The term "triazole" as used herein includes both 1,2,3-triazole and 1,2,4-triazole. When the linkage group is triazole, the aliphatic or alicyclic backbone and the at least two halogen-substituted aromatic group are linked through one of the two carbon atoms, and the nitrogen atom at the 4 position in the case of 1,2,4-triazole or the nitrogen atom at the 3 position in the case of 1,2,3-triazole.
The aliphatic backbones suitable for the present invention include, but are not limited to: ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and analogs or isomers thereof. The alicyclic backbones suitable for the present invention include, but are not limited to: cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooxtanene, and analogs or isomers thereof. Preferably, the aliphatic or alicyclic backbone is an aliphatic or alicyclic moiety having 4 to 8 carbon atoms.
It is preferable that the radiographic contrasting agent of the present invention contains at least three halogen-substituted aromatic groups.
By "a halogen-substituted aromatic group", it is meant an aromatic group = CA 02568827 2006-11-24 having at least one halogen substituent. By "an aromatic group", it is meant a cyclic organic compound containing multiple conjugated double bonds. The halogen-substituted aromatic group of the present invention may be halogen-substituted carbocyclic, heterocyclic, or polycyclic compounds. Halogen-substituted aromatic groups suitable for the present invention include, but are not limited to: halogen-substituted benzene, toluene, xylenes, styrenes, pyridine, furan, naphthalene, anthracene, phenanthrene, indole, quinoline, and isoquinoline. Preferably, the halogen-substituted aromatic group of the present invention is halogen-substituted benzene. Each of the halogen-io substituted aromatic groups of the present invention is substituted with at least three halogen atoms. Preferably, the at least three halogen atoms are bromine, iodine, or combinations thereof. More preferably, the halogen-substituted aromatic group of the present invention is substituted with at least three iodine atoms. In one preferred embodiment of the present invention, the halogen-substituted aromatic group is 2,3,5-triiodobenzene.
The radiographic contrasting agent of the present invention can be prepared through reactions between an organic compound containing a polyhydric alcohol or a polyamine and an halogen-substituted aromatic compound. The organic compounds containing the polyhydric alcohol or polyamine suitable for the present invention include, but are not limited to:
ethylene glycol, propylene glycol, glycerol, pentaerythritol, trethelose, sorbitol, mannitol, xylitol, putrescine, spermidine, spermine, and analogs thereof. The radiographic contrasting agent of the present invention may also be prepared by other methods known to one skilled in the art.
In one embodiment of the present invention, the organic radiographic contrasting agent has the following structure:
DEVICES
Field of Invention The present invention relates to an organic contrasting agent that provides enhanced contrasting intensity in radiographic imaging of medical devices and a polymeric material containing the organic contrasting agent and at least one polymer.
Background of Invention It is important that medical devices are biocompatible since most medical devices interface with biological tissues during use. Therefore, medical devices are preferred to be prepared from biocompatible materials.
More specifically, the ideal materials for medical devices should satisfy at least the following requirements: (1) conformable, i.e., conform to the biological structure without inducing detrimental stress, (2) robust, i.e., withstand handling during fabrication and implantation, and (3) chemically inert to body tissue and body fluids. However, conventional materials used for the construction of medical devices, such as stainless steel and other alloys, not only are physically rigid, but also cause inflammatory reactions or other side effects when interfacing with biological tissues.
To overcome these problems, synthetic poiymeric materials, including both biodegradable and non-biodegradable polymers, have been widely used to fabricate medical devices. Common biodegradable polymers include polylactide (PLA) polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyphosphoesters (PPE), polyorthoesters, polyanhydrides, polyphosphazene, poly(esteramide) (PEA), and copolymers and mixtures thereof. Non-biodegradable polymers are also known as nonabsorbable polymers. Common nonabsorbable polymeric materials - 1 - , include, but are not limited to: silicone elastomers, polyutheranes, polymethyl methacrylate, Dacron , Teflon , and derivatives thereof. However, these polymeric materials are not radio-opaque. Consequently, medical devices made from these polymers cannot be visualized by means of radiographic imaging. The ability to see the radiographic image of a medical device being used in, or implanted within, the body is very important since radiographic imaging provides a physician the ability to monitor and adjust the medical device during operation. For some medical implant applications, X-ray visibility is mandatory.
To achieve desirable radio-opacity in the polymeric materials used for medical implants, one conventional method utilizes inorganic radiographic contrasting agents, such as barium sulfate, zirconium dioxide, or bismuth halides as additives or fillers in the polymeric material to form a radio-opaque polymeric matrix. However, these inorganic agents do not mix well with polymeric materials and may cause phase separation or even clumps in the radio-opaque polymeric matrix. The phase separation problem is further aggravated since high concentrations {around 10%, and often times 20-30%
by weight) of these inorganic radiographic contrasting agents -are routinely used to obtain the required radio-opacity. The incompatibility between the polymeric and inorganic phases compromises the physicomechanical properties (e.g., lubricity and robustness) of the polymer matrix. Another disadvantage of using inorganic radiographic contrasting agents is the leach-out of these inorganic agents from the radio-opaque polymeric matrix, which adversely compromises the mechanical strength of the polymeric material.
An alternative approach to introduce radio-opacity into polymeric materials is to synthesize polymers having covalently bound bromine or iodine atoms that may produce a radiographic contrasting effect (See U.S. Patent No. 6,426,145). One radio-opaque composition of the prior art comprises a polymer having a non-leachable radio-opaque moiety covalently attached to the polymer (See U.S. Patent No. 6,599,448), wherein the non-leachable radio-opaque moiety includes halogen substituted aromatic groups. The prior art has also disclosed a radio-opaque polymeric material comprising a diphenol-based monomer unit substituted with at least one bromine or iodine atom (See U.S. Patent No. 6,852,308). However, preparations of these prior art radio-opaque polymers require synthesis of radiographic contrasting monomer units, which may increase the technical complexity and production cost.
Thus, there remains a need for a radiographic contrasting agent that is compatible with polymeric materials and provides enhanced contrasting intensity as well.
Summary of the Invention Accordingly, the present invention provides a radiographic contrasting agent comprising an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)--, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -(SO)NH-, and triazole. Preferably, the inventive radiographic contrasting agent comprises at least three halogen-substituted aromatic groups.
The present invention also provides a radio-opaque polymeric material comprising an organic radiographic contrasting agent and at least one polymer, wherein the organic radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer, and the organic radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three = CA 02568827 2006-11-24 halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole. The at least one polymer may be at least one biodegradable polymer, at least one non-biodegradable polymer, or a mixture thereof.
In another aspect, the present invention provides a medical device, wherein at least one portion of the medical device is radio-opaque, the at least one radio-opaque portion of the medical device comprising a radio-opaque polymeric material, which comprises a radiographic contrasting agent and at least one polymer, wherein the radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -(SO)NH-, and triazole. Preferably, the medical device is an implantable medical device. More preferably, the medical device is a cardiovascular or peripheral drug eluting stent.
Detailed Description of the Invention The present invention provides a radiographic contrasting agent, comprising an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups. As used herein, "an aliphatic backbone" denotes an organic moiety consisting of carbon atoms linked in open chains, and "an alicyclic backbone" denotes an organic moiety consisting of carbon atoms forming one or more rings that are not aromatic.
Each of the at least two halogen-substituted aromatic groups in the inventive radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone through a linkage group. The linkage group is selected from oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -~SO)NH-, or triazole. As used herein, "(CO)" denotes a carbonyl moiety; "(SO)" denotes a sulfinyl moiety; and "(SO2)" denotes a sulfonyl moiety. The linkage group links the aliphatic or alicyclic backbone and the at least two halogen-substituted aromatic groups through covalent bonds. The linkage group expressed as "-linkage-" denotes a linkage in the manner as follows: (the aliphatic or alicyclic backbone)-linkage-(one of the at least two halogen-substituted aromatic groups). For example, -(CO)O-" denotes a linkage as follows: (the aliphatic or alicyclic backbone)-(CO)O-(one of the at least two halogen-substituted aromatic groups). Preferably, the linkage group of the present invention is -NH(CO)-, -O(CO)-, or triazole. The term "triazole" as used herein includes both 1,2,3-triazole and 1,2,4-triazole. When the linkage group is triazole, the aliphatic or alicyclic backbone and the at least two halogen-substituted aromatic group are linked through one of the two carbon atoms, and the nitrogen atom at the 4 position in the case of 1,2,4-triazole or the nitrogen atom at the 3 position in the case of 1,2,3-triazole.
The aliphatic backbones suitable for the present invention include, but are not limited to: ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and analogs or isomers thereof. The alicyclic backbones suitable for the present invention include, but are not limited to: cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooxtanene, and analogs or isomers thereof. Preferably, the aliphatic or alicyclic backbone is an aliphatic or alicyclic moiety having 4 to 8 carbon atoms.
It is preferable that the radiographic contrasting agent of the present invention contains at least three halogen-substituted aromatic groups.
By "a halogen-substituted aromatic group", it is meant an aromatic group = CA 02568827 2006-11-24 having at least one halogen substituent. By "an aromatic group", it is meant a cyclic organic compound containing multiple conjugated double bonds. The halogen-substituted aromatic group of the present invention may be halogen-substituted carbocyclic, heterocyclic, or polycyclic compounds. Halogen-substituted aromatic groups suitable for the present invention include, but are not limited to: halogen-substituted benzene, toluene, xylenes, styrenes, pyridine, furan, naphthalene, anthracene, phenanthrene, indole, quinoline, and isoquinoline. Preferably, the halogen-substituted aromatic group of the present invention is halogen-substituted benzene. Each of the halogen-io substituted aromatic groups of the present invention is substituted with at least three halogen atoms. Preferably, the at least three halogen atoms are bromine, iodine, or combinations thereof. More preferably, the halogen-substituted aromatic group of the present invention is substituted with at least three iodine atoms. In one preferred embodiment of the present invention, the halogen-substituted aromatic group is 2,3,5-triiodobenzene.
The radiographic contrasting agent of the present invention can be prepared through reactions between an organic compound containing a polyhydric alcohol or a polyamine and an halogen-substituted aromatic compound. The organic compounds containing the polyhydric alcohol or polyamine suitable for the present invention include, but are not limited to:
ethylene glycol, propylene glycol, glycerol, pentaerythritol, trethelose, sorbitol, mannitol, xylitol, putrescine, spermidine, spermine, and analogs thereof. The radiographic contrasting agent of the present invention may also be prepared by other methods known to one skilled in the art.
In one embodiment of the present invention, the organic radiographic contrasting agent has the following structure:
~ I
HN
I O -fN I 0 I
I, I
H H
I I (I) In another embodiment of the present invention, the organic radiographic contrasting agent has the following structure:
I \ / I o I o I
~ / \ I
I I
(II) The inventive radiographic contrasting agent of formula (II) is synthesized through a reaction between pentaerythritol and 2,3,5-triiodobenzoic acid in the presence of thionyl chloride, i.e., SOCI2, as shown in Scheme 1.
Scheme 1:
I /
~ ~ I O
+ 4 OH O THF / n-hexane O O O
I I
The inventive radiographic contrasting agent is sparsely solubie in water and substantially soluble in common organic solvents. By "substantial soluble", it is meant having a solubility of about 10 mg per milliliter or above. By "sparsely soluble", it is meant having a solubility of about 1 mg per milliliter or below. Particularly, unlike the inorganic radiographic contrasting agents, the inventive radiographic contrasting agent readily dissolves or disperses in organic solvents used to dissolve various polymers, such as dimethylacetamide (DMAC), dimethylformide (DMF), N-methylpyrrolidone (NMP), dimethylsulfoxide (DMSO), tetrahydrofuran (THF), 1,4-dioxane, and chlorinated solvents (e.g., dichloromethane). Thus, the inventive radiographic contrasting agent is miscible with various polymers used for the construction of medical devices. Due to its sparse solubility in lo water, the inventive radiographic contrasting agent does not swell the polymer matrices resulted from physically admixing the inventive radiographic contrasting agent and one or more polymers. The inventive radiographic contrasting agent only leaches out of the polymer matrices in such a very slow process that the mechanical strength and/or the degradation profile of the polymer matrices are not adversely compromised. Furthermore, when the inventive radiographic contrasting agent is admixed with one or more polymers, the inventive radiographic contrasting agent does not form any clumps or cause any phase separation in the resulting polymer matrices.
Therefore, the polymer matrices of the inventive radiographic contrasting agent and one or more polymers retain the smoothness and lubricity of the one or more polymers. Moreover, the polymer matrices of the inventive radiographic contrasting agent and one or more polymers either retain the mechanical strength of the one or more polymers or show enhanced mechanical strength. In addition, the inventive radiographic contrasting agent contains multiple halogen atoms in a small, single organic compound resulting in a very high contrasting intensity. Thus, a comparatively small quantity of the inventive radiographic contrasting agent in polymer matrices is able to impart sufficient image quality, and consequently the polymer matrices have more capacity to load therapeutic agents or other functional molecules.
The present invention also provides a radio-opaque polymeric material comprising a radiographic contrasting agent and at least one polymer. The radiographic contrasting agent in the inventive radio-opaque poiymer9c material is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer. The radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and each of the at least two halogen-substituted aromatic groups is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(SO2)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole. Preferably, the radiographic contrasting agent of the present invention comprises at least three halogen-substituted aromatic groups.
The at least one polymer of the present invention may be any polymer compatible with the inventive radiographic contrasting agent.
Preferably, the at least one polymer may be at least one biodegradable polymer, at least one non-biodegradable polymer, or a mixture thereof. By "biodegradable polymer", it is meant a polymer that can be degraded or decomposed by natural biological processes, as by the action of bacteria, plants, or animals. Biodegradable polymers are also known as bioabsorbable polymers or biodissolvable polymers. Biodegradable polymers suitable for the present invention include, but are not limited to: polyglycolide, polylactide, poly(lactide-co-glycolide), polydioxanone, polycaprolactone, polyhydroxybutyrate, poly(trimethylene carbonate), polyphosphoesters (PPE), polyorthoesters, polyanhydrides, polyphosphazene, poly(ester amide), and copolymers and mixtures thereof. Non-biodegradable polymers suitable for the present invention include, but are not limited to: silicone elastomers, poly(ethylene-co-vinyl acetate), polyacrylates, polymethacrylates, polyethylene oxide, polystyrene, polyurethanes, polyamides, and copolymers and mixtures thereof.
HN
I O -fN I 0 I
I, I
H H
I I (I) In another embodiment of the present invention, the organic radiographic contrasting agent has the following structure:
I \ / I o I o I
~ / \ I
I I
(II) The inventive radiographic contrasting agent of formula (II) is synthesized through a reaction between pentaerythritol and 2,3,5-triiodobenzoic acid in the presence of thionyl chloride, i.e., SOCI2, as shown in Scheme 1.
Scheme 1:
I /
~ ~ I O
+ 4 OH O THF / n-hexane O O O
I I
The inventive radiographic contrasting agent is sparsely solubie in water and substantially soluble in common organic solvents. By "substantial soluble", it is meant having a solubility of about 10 mg per milliliter or above. By "sparsely soluble", it is meant having a solubility of about 1 mg per milliliter or below. Particularly, unlike the inorganic radiographic contrasting agents, the inventive radiographic contrasting agent readily dissolves or disperses in organic solvents used to dissolve various polymers, such as dimethylacetamide (DMAC), dimethylformide (DMF), N-methylpyrrolidone (NMP), dimethylsulfoxide (DMSO), tetrahydrofuran (THF), 1,4-dioxane, and chlorinated solvents (e.g., dichloromethane). Thus, the inventive radiographic contrasting agent is miscible with various polymers used for the construction of medical devices. Due to its sparse solubility in lo water, the inventive radiographic contrasting agent does not swell the polymer matrices resulted from physically admixing the inventive radiographic contrasting agent and one or more polymers. The inventive radiographic contrasting agent only leaches out of the polymer matrices in such a very slow process that the mechanical strength and/or the degradation profile of the polymer matrices are not adversely compromised. Furthermore, when the inventive radiographic contrasting agent is admixed with one or more polymers, the inventive radiographic contrasting agent does not form any clumps or cause any phase separation in the resulting polymer matrices.
Therefore, the polymer matrices of the inventive radiographic contrasting agent and one or more polymers retain the smoothness and lubricity of the one or more polymers. Moreover, the polymer matrices of the inventive radiographic contrasting agent and one or more polymers either retain the mechanical strength of the one or more polymers or show enhanced mechanical strength. In addition, the inventive radiographic contrasting agent contains multiple halogen atoms in a small, single organic compound resulting in a very high contrasting intensity. Thus, a comparatively small quantity of the inventive radiographic contrasting agent in polymer matrices is able to impart sufficient image quality, and consequently the polymer matrices have more capacity to load therapeutic agents or other functional molecules.
The present invention also provides a radio-opaque polymeric material comprising a radiographic contrasting agent and at least one polymer. The radiographic contrasting agent in the inventive radio-opaque poiymer9c material is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer. The radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and each of the at least two halogen-substituted aromatic groups is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(SO2)O-, -O(SO)-, -(SO)O-, -NH(S02)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole. Preferably, the radiographic contrasting agent of the present invention comprises at least three halogen-substituted aromatic groups.
The at least one polymer of the present invention may be any polymer compatible with the inventive radiographic contrasting agent.
Preferably, the at least one polymer may be at least one biodegradable polymer, at least one non-biodegradable polymer, or a mixture thereof. By "biodegradable polymer", it is meant a polymer that can be degraded or decomposed by natural biological processes, as by the action of bacteria, plants, or animals. Biodegradable polymers are also known as bioabsorbable polymers or biodissolvable polymers. Biodegradable polymers suitable for the present invention include, but are not limited to: polyglycolide, polylactide, poly(lactide-co-glycolide), polydioxanone, polycaprolactone, polyhydroxybutyrate, poly(trimethylene carbonate), polyphosphoesters (PPE), polyorthoesters, polyanhydrides, polyphosphazene, poly(ester amide), and copolymers and mixtures thereof. Non-biodegradable polymers suitable for the present invention include, but are not limited to: silicone elastomers, poly(ethylene-co-vinyl acetate), polyacrylates, polymethacrylates, polyethylene oxide, polystyrene, polyurethanes, polyamides, and copolymers and mixtures thereof.
The inventive radiographic contrasting agent may be physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer in any manner known to one skilled in the art. In one embodiment of the present invention, the inventive radiographic contrasting agent is dissolved in an organic solvent, and the resulting solution is then admixed with a solution of at least one polymer in the organic solvent. In another embodiment of the present invention, the inventive radiographic contrasting agent is directly dissolved in a solution of at least one polymer in an organic solvent.
The weight ratio of the inventive radiographic contrasting agent to the at least one polymer varies depending upon the structure of the inventive radiographic contrasting agent and the desired radio-opacity of the polymeric material. Typically, the weight ratio of the inventive radiographic contrasting agent to the at least one polymer is less than about 20:100.
Preferably, the weight ratio of the inventive radiographic contrasting agent to the at least one polymer is less than about 10:100.
The inventive radio-opaque polymeric material not oniy possesses the desirable biocompatibility and physicomechanical properties (e.g., strength, fatigue, smoothness), but also has radio-opacity for visualization in radiographic imaging. The mechanical strength and/or the degradation time of the radio-opaque polymeric material can be tuned by adjusting the molecular weight or composition of the at least one polymer.
The radiographic contrast intensity of the inventive biodegradable polymer can be adjusted by varying the ratio of the inventive radiographic contrasting agent and the at least one polymer. The inventive radiographic contrasting agent is soluble in organic solvents and miscible with the bulk polymeric materials used to construct a medical device. Therefore, the inventive radio-opaque polymeric material is suitable for medical devices, particularly those interfacing with biological tissues, such as implantable medical devices.
The weight ratio of the inventive radiographic contrasting agent to the at least one polymer varies depending upon the structure of the inventive radiographic contrasting agent and the desired radio-opacity of the polymeric material. Typically, the weight ratio of the inventive radiographic contrasting agent to the at least one polymer is less than about 20:100.
Preferably, the weight ratio of the inventive radiographic contrasting agent to the at least one polymer is less than about 10:100.
The inventive radio-opaque polymeric material not oniy possesses the desirable biocompatibility and physicomechanical properties (e.g., strength, fatigue, smoothness), but also has radio-opacity for visualization in radiographic imaging. The mechanical strength and/or the degradation time of the radio-opaque polymeric material can be tuned by adjusting the molecular weight or composition of the at least one polymer.
The radiographic contrast intensity of the inventive biodegradable polymer can be adjusted by varying the ratio of the inventive radiographic contrasting agent and the at least one polymer. The inventive radiographic contrasting agent is soluble in organic solvents and miscible with the bulk polymeric materials used to construct a medical device. Therefore, the inventive radio-opaque polymeric material is suitable for medical devices, particularly those interfacing with biological tissues, such as implantable medical devices.
In another aspect, the present invention provides a medical device, wherein at least one portion of the medical device is radio-opaque, the at least one radio-opaque portion of the medical device comprising a radio-opaque polymeric material, which comprises a radiographic contrasting agent and at least one polymer, wherein the radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer, and the radiographic contrasting agent comprises an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least lo two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(S02)O-, -O(SO}-, -{SO)O-, -NH(S02)-, -(S02)NH-, -NH(SO)-, -(SO)NH-, and triazole.
In the present invention, the radio-opaque portion of the medical device may be at least a portion of one surface of the medical device, a component of the medical device, or a portion of a component of the medical device. The radio-opaque portion of the medical device may be in any shape or size depending upon the intended use and the fabrication method of the medical device. When all surfaces of the medical device are coated with the inventive radio-opaque biodegradable polymeric material or the whole medical device is prepared from the inventive radio-opaque biodegradable polymeric material, the whole medical device is radio-opaque. Preferably, the medical device of the present invention is an implantable medical device. More preferably, the implantable medical device is a cardiovascular or peripheral drug eluting stent. Examples of the medical devices suitable for the present invention include, but are not limited to: wound closure devices, such as, sutures, staples, and mesh; orthopedic fixation devices, such as, bone fracture fixation implants and bone augmentation implants; intestinal devices, such as, anastomosis rings and ligating clips; cardiovascular devices, such as, vascular grafts, and cardiovascular or peripheral drug elution stents;
In the present invention, the radio-opaque portion of the medical device may be at least a portion of one surface of the medical device, a component of the medical device, or a portion of a component of the medical device. The radio-opaque portion of the medical device may be in any shape or size depending upon the intended use and the fabrication method of the medical device. When all surfaces of the medical device are coated with the inventive radio-opaque biodegradable polymeric material or the whole medical device is prepared from the inventive radio-opaque biodegradable polymeric material, the whole medical device is radio-opaque. Preferably, the medical device of the present invention is an implantable medical device. More preferably, the implantable medical device is a cardiovascular or peripheral drug eluting stent. Examples of the medical devices suitable for the present invention include, but are not limited to: wound closure devices, such as, sutures, staples, and mesh; orthopedic fixation devices, such as, bone fracture fixation implants and bone augmentation implants; intestinal devices, such as, anastomosis rings and ligating clips; cardiovascular devices, such as, vascular grafts, and cardiovascular or peripheral drug elution stents;
dental implants; nerve growth conduits; guiding wires, catheters, and other implantable medical devices. The inventive radio-opaque biodegradable polymeric material may be applied on at least a portion of one surface of a medical device as a coating using cast, spray, spin, dipping, or other methods known to one skilled in the art. The medical device or a component thereof can be constructed from the inventive radio-opaque biodegradable polymeric material using solvent casting, injection molding, compression molding, extrusion, or other methods know to one skilled in the art to construct polymeric medical devices.
The following non-limiting example is provided to further illustrate the present invention. Because the example is provided for illustrative purpose only, the invention embodied therein should not be limited thereto.
Example: Synthesis of a radiographic contrasting agent of formula (I) The inventive radiographic contrasting agent of formula (I) was prepared through the synthetic route as shown in Scheme 2:
Scheme 2:
SOCIZ/THF
O CI
Reflux (111) ( t1~
I
N 1 p O
r-I CI HN ~\ 1 N, + 3.6 TEA/THF F-I
S / - -M N (IV) I N
H N
H
I
(1) A mixture of compound llll) (40g, 0.08 mol) and thionyl chloride (20g, 0.017 mol) in THF (300 mL) was heated to reflux for 40 minutes. Then the solvent was removed by a rotavapor. The resulting dry solid was re-crystallized in hexane. This process provided 20g of compound (IV), which had a yield of 49%.
To a solution of compound (V) (4.06g, 0.028 mol) in THF (400 mL) and triethylamine (16 mL), i.e., TEA, was slowly added a solution of compound (IV) (51.8g, 0.1 mol) in THF (150 mL) at 0 to 5 C in a period of 10 to 15 minutes. The resulting reaction mixture was then stirred at room temperature for 2 hours. Next, the reaction mixture was added to 1000 mL of lo water. The solid was collected by filtration, washed with saturated sodium carbonate (3 X 100 mL), water (3 X100 mL), and warm methanol ( 3 X 100 mL, 45-50 C). Compound (IV) (43g) was obtained with a yield of 96% and a purity of above 95% (determined by H'NMR). H'NMR (DMSO-d6): 8.39(s, 3H); 8.26(s, 3H); 7.56(s, 3H); 3.36(br, 6H); 2.69(br, 6H). MS(+): 1592; MS(-):
1590.
While the present invention has been particularly shown and described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that the foregoing and other changes in forms and details may be made without departing from the spirit and scope of the invention. It is therefore intended that the present invention not be limited to the exact forms and details described and illustrated but fall within the scope of the appended claims.
The following non-limiting example is provided to further illustrate the present invention. Because the example is provided for illustrative purpose only, the invention embodied therein should not be limited thereto.
Example: Synthesis of a radiographic contrasting agent of formula (I) The inventive radiographic contrasting agent of formula (I) was prepared through the synthetic route as shown in Scheme 2:
Scheme 2:
SOCIZ/THF
O CI
Reflux (111) ( t1~
I
N 1 p O
r-I CI HN ~\ 1 N, + 3.6 TEA/THF F-I
S / - -M N (IV) I N
H N
H
I
(1) A mixture of compound llll) (40g, 0.08 mol) and thionyl chloride (20g, 0.017 mol) in THF (300 mL) was heated to reflux for 40 minutes. Then the solvent was removed by a rotavapor. The resulting dry solid was re-crystallized in hexane. This process provided 20g of compound (IV), which had a yield of 49%.
To a solution of compound (V) (4.06g, 0.028 mol) in THF (400 mL) and triethylamine (16 mL), i.e., TEA, was slowly added a solution of compound (IV) (51.8g, 0.1 mol) in THF (150 mL) at 0 to 5 C in a period of 10 to 15 minutes. The resulting reaction mixture was then stirred at room temperature for 2 hours. Next, the reaction mixture was added to 1000 mL of lo water. The solid was collected by filtration, washed with saturated sodium carbonate (3 X 100 mL), water (3 X100 mL), and warm methanol ( 3 X 100 mL, 45-50 C). Compound (IV) (43g) was obtained with a yield of 96% and a purity of above 95% (determined by H'NMR). H'NMR (DMSO-d6): 8.39(s, 3H); 8.26(s, 3H); 7.56(s, 3H); 3.36(br, 6H); 2.69(br, 6H). MS(+): 1592; MS(-):
1590.
While the present invention has been particularly shown and described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that the foregoing and other changes in forms and details may be made without departing from the spirit and scope of the invention. It is therefore intended that the present invention not be limited to the exact forms and details described and illustrated but fall within the scope of the appended claims.
Claims (20)
1. A radiographic contrasting agent comprising an aliphatic or alicyclic backbone of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(SO2)O-, -O(SO)-, -(SO)O-, -NH(SO2)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole.
2. A radiographic contrasting agent of claim 1, comprising at least three halogen-substituted aromatic groups.
3. A radiographic contrasting agent of claim 2, wherein the linkage group is -NH(CO)-, -O(CO)-, or triazole.
4. A radiographic contrasting agent of claim 3, wherein the at least halogen atoms are bromine, iodine, or combinations thereof.
5. A radiographic contrasting agent of claim 1, having the following structure:
6. A radiographic contrasting agent of claim 1, having the following structure:
7. A radio-opaque polymeric material, comprising a radiographic contrasting agent and at least one polymer, wherein the radiographic contrasting agent comprises an aliphatic or alicyclic group of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic group through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(SO2)O-, -O(SO)-, -(SO)O-, -NH(SO2)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole.
8. A radio-opaque polymeric material of claim 7, wherein the radiographic contrasting agent comprises at least three halogen-substituted aromatic groups.
9. A radio-opaque polymeric material of claim 8, wherein the linkage group is -NH(CO)-, or -O(CO)-, or triazole.
10. A radio-opaque polymeric material of claim 9, wherein the at least three halogen atoms are bromine, iodine, or combinations thereof.
11. A radio-opaque polymeric material of claim 7, wherein the at least one polymer is at least one biodegradable polymer, at least one non-biodegradable polymer, or a mixture thereof.
12. A radio-opaque polymeric material of claim 11, wherein the at least one biodegradable polymer is selected from the group consisting of polylactide (PLA) polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyphosphoesters (PPE), polyorthoesters, polyanhydrides, polyphosphazene, poly(esteramide) (PEA), and copolymers and mixtures thereof.
13. A radio-opaque polymeric material of claim 11, wherein the at least one non-biodegradable polymer is selected from the group consisting of silicone elastomers, poly(ethylene-co-vinyl acetate), polyacrylates, polymethacrylates, polyethylene oxide, polystyrene, polyurethanes, polyamides, and copolymers and mixtures thereof.
14. A medical device, wherein at least one portion of the medical device is radio-opaque, the at least one radio-opaque portion of the medical device comprising a radio-opaque polymeric material, which comprises a radiographic contrasting agent and at least one polymer, wherein the radiographic contrasting agent comprises an aliphatic or alicyclic group of 2 to 12 carbon atoms and at least two halogen-substituted aromatic groups, wherein each of the at least two halogen-substituted aromatic groups is substituted with at least three halogen atoms, and is covalently attached to the aliphatic or alicyclic group through a linkage group, wherein the linkage group is selected from the group consisting of oxygen, sulfur, -NH-, -O(CO)-, -(CO)O-, -NH(CO)-, -(CO)NH-, -O(SO2)-, -(SO2)O-, -O(SO)-, -(SO)O-, -NH(SO2)-, -(SO2)NH-, -NH(SO)-, -(SO)NH-, and triazole.
15. A medical device of claim 14, wherein the radiographic contrasting agent comprises at least three halogen-substituted aromatic groups.
16. A medical device of claim 14, wherein the at least one biodegradable polymer is selected from the group consisting of polylactide (PLA) polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyphosphoesters (PPE), polyorthoesters, polyanhydrides, polyphosphazene, poly(ester amide) (PEA), and copolymers and mixtures thereof.
17. A medical device of claim 14, wherein the at least one non-biodegradable polymer is selected from the group consisting of silicone elastomers, poly(ethylene-co-vinyl acetate), polyacrylates, polymethacrylates, polyethylene oxide, polystyrene, polyurethanes, polyamides, and copolymers and mixtures thereof.
18. A medical device of claim 14, wherein the radio-opaque portion of the medical device is at least a portion of one surface of the medical device, a component of the medical device, or a portion of a component of the medical device.
19. A medical device of claim 14, wherein said medical device is implantable.
20. A medical device of claim 14, wherein said medical device is a cardiovascular or peripheral drug eluting stent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/296,606 | 2005-12-07 | ||
| US11/296,606 US7407647B2 (en) | 2005-12-07 | 2005-12-07 | Organic radiographic contrasting agents for medical devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2568827A1 true CA2568827A1 (en) | 2007-06-07 |
| CA2568827C CA2568827C (en) | 2014-05-13 |
Family
ID=37912679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2568827A Expired - Fee Related CA2568827C (en) | 2005-12-07 | 2006-11-24 | Organic radiographic contrasting agents for medical devices |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7407647B2 (en) |
| EP (1) | EP1795209B1 (en) |
| JP (1) | JP2007153895A (en) |
| AT (1) | ATE447975T1 (en) |
| CA (1) | CA2568827C (en) |
| DE (1) | DE602006010309D1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE307110T1 (en) * | 1997-11-07 | 2005-11-15 | Univ Rutgers | RADIATION TRANSPARENT POLYMERIC BIOMATERIAL |
| US20080306495A1 (en) * | 2007-06-07 | 2008-12-11 | Thompson Ronald J | Transilluminating laparoscopic ligating vascular clamp (LVC) |
| WO2012133295A1 (en) * | 2011-03-30 | 2012-10-04 | 株式会社ジェイ・エム・エス | Bioabsorbable antiadhesive material containing contrast medium |
| CN102295736A (en) * | 2011-06-03 | 2011-12-28 | 大连理工大学 | Preparation method of polylactic acid material with X-ray developing functions |
| CN103007301B (en) * | 2012-12-29 | 2014-10-29 | 上海师范大学 | Ferroferric oxide nano particles with CT/MRI (Computed Tomography/Magnetic Resonance Imaging) double functions as well as preparation method and application thereof |
| JP6478508B2 (en) * | 2014-07-24 | 2019-03-06 | 旭化成株式会社 | Polyphenylene ether containing liquid |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3734953A (en) * | 1969-08-11 | 1973-05-22 | Squibb & Sons Inc | Tris-triiodoisophthalamic acids and derivatives |
| US4873075A (en) * | 1985-09-10 | 1989-10-10 | The University Of Michigan | Polyiodinated triglyceride analogs as radiologic agents |
| IT1245853B (en) | 1990-11-16 | 1994-10-25 | Bracco Spa | 1,3-BIS (3- (MONO OR POLYHYDROXY) ACYLAMINE-5- (MONO OR POLYHYDROXY-ALCHYL) AMINOCARBONYL-2,4,6-TRIIODE-BENZOYL-AMINO) -HYDROXY- OR HYDROXY-ALCHYL-PROPANE, THEIR METHOD OF PREPARATION AND ROENTGENOGRAPHIC CONTRAST MEANS THAT CONTAIN THEM |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| ATE307110T1 (en) * | 1997-11-07 | 2005-11-15 | Univ Rutgers | RADIATION TRANSPARENT POLYMERIC BIOMATERIAL |
| US6426145B1 (en) * | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
| US6599448B1 (en) * | 2000-05-10 | 2003-07-29 | Hydromer, Inc. | Radio-opaque polymeric compositions |
| US20060292077A1 (en) | 2005-03-18 | 2006-12-28 | Zhao Jonathon Z | Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same |
-
2005
- 2005-12-07 US US11/296,606 patent/US7407647B2/en not_active Expired - Fee Related
-
2006
- 2006-11-24 CA CA2568827A patent/CA2568827C/en not_active Expired - Fee Related
- 2006-12-06 AT AT06256221T patent/ATE447975T1/en not_active IP Right Cessation
- 2006-12-06 EP EP06256221A patent/EP1795209B1/en not_active Not-in-force
- 2006-12-06 JP JP2006329761A patent/JP2007153895A/en not_active Withdrawn
- 2006-12-06 DE DE602006010309T patent/DE602006010309D1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20070128120A1 (en) | 2007-06-07 |
| EP1795209A3 (en) | 2008-01-23 |
| DE602006010309D1 (en) | 2009-12-24 |
| EP1795209B1 (en) | 2009-11-11 |
| JP2007153895A (en) | 2007-06-21 |
| ATE447975T1 (en) | 2009-11-15 |
| US7407647B2 (en) | 2008-08-05 |
| EP1795209A2 (en) | 2007-06-13 |
| CA2568827C (en) | 2014-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2570410C (en) | Radiographic contrasting agents and radio-opaque polymeric materials for medical devices | |
| CA2568827C (en) | Organic radiographic contrasting agents for medical devices | |
| James et al. | Polyurethanes with radiopaque properties | |
| US9212259B2 (en) | Nitric oxide delivery system using thermosensitive synthetic polymers | |
| JP5581202B2 (en) | Dihydroxybenzoate polymer and use thereof | |
| JP4104656B2 (en) | Composition for imaging of gastrointestinal tract comprising triiodobenzene polymer | |
| JP6592437B2 (en) | Polymeric biomaterials derived from monomers containing hydroxy acids and phenolic compounds and their medical use | |
| BRPI0613018A2 (en) | Resorbable polyether esters and their use in the production of medical implants | |
| JP6543831B2 (en) | Polymer composition having enhanced radiopacity | |
| US20210402051A1 (en) | A radiopaque polymeric liquid embolic system | |
| JP2021524876A (en) | Biodegradable polymer | |
| James et al. | On imparting radiopacity to a poly (urethane urea) | |
| JP5892610B2 (en) | Hydrophobic polymers for manufacturing medical devices visible in MRI | |
| JP6207520B2 (en) | MRI visible hydrophobic copolymer | |
| US20220242817A1 (en) | Iodinated compounds having radiocontrast properties | |
| JP2020530054A (en) | Poly (ester urea) for shape memory and drug delivery | |
| US20040022732A1 (en) | Microparticles based on aspartic acid and use thereof as mri contrast agents | |
| Kiran et al. | Inherently X-ray opaque polyurethane microspheres for biomedical applications | |
| KR20060062359A (en) | Biodegradable polymer film for drug eluting stent and covering method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20191125 |